The Study Will Evaluate the Efficacy of AZD5423 in Patients With Mild Asthma Challenged With an Inhaled Allergen

NCT01225549 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

DRUG: AZD5423
DRUG: Budesonide 200 microgram
DRUG: Placebo
DRUG: Placebo

Sponsor

AstraZeneca